Obsidian Therapeutics, Inc.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Holding
- Established
- 2015-01-01
- Employees
- 51
- Market Cap
- -
- Website
- http://www.obsidiantx.com
Safety and Efficacy of OBX-115 in Advanced Solid Tumors
Phase 1
Recruiting
- Conditions
- Tumor SkinLung CancerNon Small Cell Lung CancerMelanomaMetastatic Lung CancerMetastatic MelanomaMetastatic Non Small Cell Lung Cancer
- Interventions
- First Posted Date
- 2023-09-29
- Last Posted Date
- 2025-04-27
- Lead Sponsor
- Obsidian Therapeutics, Inc.
- Target Recruit Count
- 52
- Registration Number
- NCT06060613
- Locations
- 🇺🇸
The Ohio State University, Columbus, Ohio, United States
🇺🇸The Angeles Clinic and Research Institute (Melanoma), Los Angeles, California, United States
🇺🇸USC Norris Comprehensive Cancer Center (Melanoma/NSCLC), Los Angeles, California, United States
© Copyright 2025. All Rights Reserved by MedPath